ArticleJournal of cardiothoracic surgery2026
Myectomy with secondary chordal resection in hypertrophic obstructive cardiomyopathy: the mid-term outcomes.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIt is not clear whether septal myectomy with secondary chordal resection (SM-SCR) can achieve similar postoperative outcomes among hypertrophic obstructive cardiomyopathy (HOCM) patients exhibiting different severity of septal hypertrophy.
methodsThis was a single-center retrospective cohort study with a nested case-control study. HOCM patients received SM-SCR between 2014 and 2023 were retrospectively included and were grouped based on their septal thickness. The main outcome was the relief of the left ventricular outflow tract (LVOT) obstruction. Besides, predictors for recurrent mitral regurgitation (MR) were also explored.
resultsA total of 88 patients were included, with 63 in the significant hypertrophy group (SH group) and 25 in the mild hypertrophy group (MH group). The overall median follow-up time was 54.0 (33.0-79.0) months. Before adjusting the covariates, The LVOT gradients at the last follow-up were similar between groups [SH group vs. MH group: 10.0 (6.0-14.0) mmHg vs. 8.0 (6.0-11.5) mmHg, P = 0.556], while the interventricular septum (IVS) was thicker for the SH group [15.0 (12.0-17.0) mm vs. 13.0 (11.0-14.0) mm, P = 0.016]. In the fully adjusted model, both the LVOT gradients and the IVS thickness were comparable (P = 0.606 and 0.520 respectively). The risk of recurrent MR was similar between groups (7.9% vs. 8.0%, log-rank P = 0.879), while no predictors for recurrent MR were identified.
conclusionAccording to our single-center data, the mid-term outcomes after SM-SCR were comparable for HOCM patients with different severity of septal hypertrophy. However, further investigations with larger sample sizes and longer follow-up durations are needed.
trial registrationThe study was approved by the Institutional Review Board [2023(2408)], and patients' consents were waived due to the retrospective nature of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.